Target intelligence / Profile preview

Dengue virus serotype 3 viral antigens (DENV-3 antigens)

Target
DENV-3 antigens
Molecular classification
Viral protein, Other
01

Overview

Dengue virus serotype 3 (DENV-3) viral antigens, primarily the envelope (E) glycoprotein and nonstructural protein 1 (NS1), serve as critical targets for the development of vaccines and therapeutic monoclonal antibodies. The E glycoprotein is the major structural protein on the virion surface, mediating host cell receptor binding and membrane fusion, while NS1 is a secreted glycoprotein essential for viral replication and immune evasion. These antigens are highly immunogenic and elicit serotype-specific neutralizing antibody responses. However, because DENV-3 is genetically and antigenically distinct from the other three dengue serotypes (DENV-1, -2, and -4), targeting these antigens requires careful design to avoid antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies facilitate viral entry into host cells and exacerbate disease severity. Therapeutic strategies targeting DENV-3 antigens include tetravalent live-attenuated vaccines like TAK-003 and CYD-TDV, which incorporate DENV-3 structural proteins, as well as investigational monoclonal antibodies such as VIS513, AV-1, and the highly potent DENV-3-specific antibody 5J7.

Other names
DENV3 antigensDENV-3 viral antigensDengue virus type 3 antigensDengue virus serotype 3 proteinsDENV-3 envelope glycoproteinDENV-3 NS1 antigen
02

Mechanism of action

Active immunization to elicit protective neutralizing antibodies (vaccines); Passive immunization via direct neutralization of viral envelope proteins to block viral entry and fusion (monoclonal antibodies).

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Antibody-dependent enhancement (ADE) leading to severe dengue (dengue hemorrhagic fever or dengue shock syndrome) upon subsequent heterologous infectionOriginal antigenic sin or molecular imprinting restricting the production of new serotype-specific antibodiesIncomplete or unbalanced serotype protection, particularly lower efficacy against DENV-3 in seronegative individuals
06

Interacting drugs

TAK-003 (Qdenga)

4 more in the full profile.

07

Biomarkers

DENV-3 NS1 antigenDENV-3 viral RNAAnti-DENV-3 IgM antibodiesAnti-DENV-3 IgG antibodies

Beyond the preview

Go deeper on Dengue virus serotype 3 viral antigens (DENV-3 antigens).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dengue virus serotype 3 viral antigens (DENV-3 antigens).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call